<DOC>
	<DOCNO>NCT00166504</DOCNO>
	<brief_summary>This efficacy safety study Vytorin ( ezetimibe ( + ) simvastatin ) compare atorvastatin ( ezetimibe/simvastatin ) week 6 primary hypercholesterolemia patient Korea . The primary hypothesis test daily administration Vytorin result great reduction low density lipoprotein cholesterol ( LDL-C ) concentration baseline 6 week treatment compare atorvastatin .</brief_summary>
	<brief_title>Ezetimibe Plus ( + ) Simvastatin Versus Atorvastatin Comparative Study ( 0653A-092 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Ezetimibe , Simvastatin Drug Combination</mesh_term>
	<criteria>Clinical diagnosis hypercholesterolemia LDLC &gt; /= 130 mg/dL &lt; /=250 mg/dL triglyceride ( TG ) &lt; /= 350 mg/dL National Cholesterol Education Program ( NCEP ) Adult Treatment Panel ( ATP ) III guideline Hypersensitivity 3hydroxy3methylglutarylCoA reductase ( HMGCoA reductase ) inhibitor Ezetimibe</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>